ProQR Partners with Ginkgo Bioworks for AI-Enabled RNA Discovery and Forms AI Advisory Board

On April 8, 2026, ProQR Therapeutics N.V. announced a strategic partnership with Ginkgo Bioworks to accelerate drug discovery for its Axiomer™ RNA editing technology platform. Through this collaboration, ProQR will gain access to Ginkgo’s autonomous lab, Nebula, which utilizes over 50 instruments to enable high-throughput data generation. This partnership aims to remove bottlenecks in data generation, improving the speed and predictive capabilities of ProQR’s AI-enabled discovery models. In conjunction with the deal, Ginkgo made a strategic equity investment in ProQR. Additionally, ProQR established an AI Advisory Board featuring experts from NVIDIA, Hugging Face, and Owkin to guide its techbio strategy. The company reported that its first AI-discovered development candidate is expected to enter clinical trials, with a Clinical Trial Application (CTA) filing anticipated in mid-2026. Initial clinical data from this program is projected by year-end 2026. ProQR also continues to advance its lead candidate, AX-0810, for cholestatic diseases.